

## EQA round: CSFB1/23 - Cerebrospinal Fluid Analysis

Deadline: 28.3.2023

Setup: groups - manufacturer of kit; Slovakia; minimal size of the groups n = 5

RoM = robust average

SD = standard deviation

CV = coefficient of variation

N<sub>tot</sub> = total number of the resultsN<sub>out</sub> = number of the results removed before calculation

AV = assigned value

CVP = consensus of all participants

U<sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)D<sub>max</sub> = acceptable difference

LL = lower limit

UL = upper limit

N<sub>eva</sub> = number of the results assessedN<sub>suc</sub> = number of successful resultsS<sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability					N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]	
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(333) Albumin</b>	[mg/L]				14							14	14	100	
<b>Sample A</b>												14	14	100	
Other					14	0						14			
							1x 12, 4x 58, 2x 60, 1x 75, 1x 91, 3x 149, 1x 162, 1x 179								
<b>Sample B</b>												14	14	100	
Other					14	0						14			
							1x 12, 4x 58, 2x 60, 1x 75, 1x 91, 3x 149, 1x 162, 1x 179								
<b>(330) Total protein</b>	[mg/L]				15							15	15	100	
<b>Sample A</b>		363	23	6,4	15		CVP	370	5,9	27%	270	470	15	15	100
(58) Beckman Coulter (AU)		373	9,1	2,4	6	0							6		
Other					9	0							9		
								1x 1, 3x 60, 1x 75, 1x 77, 1x 85, 1x 178, 1x 998							
<b>Sample B</b>		943	46	4,8	15		CVP	952	11	27%	694	1210	15	15	100
(58) Beckman Coulter (AU)		960	40	4,2	6	0							6		
Other					9	0							9		
								1x 1, 3x 60, 1x 75, 1x 77, 1x 85, 1x 178, 1x 998							
<b>(331) Glucose</b>	[mmol/L]				15							15	15	100	
<b>Sample A</b>		3,19	0,089	2,8	15		CVP	3,23	0,024	18%	2,64	3,82	15	15	100
(58) Beckman Coulter (AU)		3,16	0,015	0,47	7	0							7		
Other					8	0							8		
								3x 46, 3x 60, 1x 75, 1x 188							
<b>Sample B</b>		1,64	0,038	2,3	15		CVP	1,66	0,013	18%	1,36	1,96	15	15	100
(58) Beckman Coulter (AU)		1,64	0,037	2,3	7	0							7		
Other					8	0							8		
								3x 46, 3x 60, 1x 75, 1x 188							
<b>(335) IgA</b>	[mg/L]				4							4	4	100	
<b>Sample A</b>												4	4	100	
Other					4	0						4			
								1x 12, 1x 91, 2x 149							
<b>Sample B</b>												4	4	100	
Other					4	0						4			
								1x 12, 1x 91, 2x 149							
<b>(334) IgG</b>	[mg/L]				10							10	10	100	
<b>Sample A</b>												10	10	100	
Other					10	0						10			
								1x 12, 1x 58, 1x 60, 2x 91, 4x 149, 1x 162							
<b>Sample B</b>												10	10	100	
Other					10	0						10			
								1x 12, 1x 58, 1x 60, 2x 91, 4x 149, 1x 162							
<b>(336) IgM</b>	[mg/L]				5							5	5	100	
<b>Sample A</b>												5	5	100	
Other					5	0						5			
								1x 12, 1x 91, 3x 149							
<b>Sample B</b>												5	5	100	
Other					5	0						5			
								1x 12, 1x 91, 3x 149							
<b>(338) Lactate</b>	[mmol/L]				14							14	13	93	
<b>Sample A</b>		1,82	0,093	5,1	14		CVP	1,83	0,023	20%	1,46	2,2	14	13	93
(58) Beckman Coulter (AU)		1,75	0,059	3,4	5	0							5		
Other					9	0							9		
								1x 1, 3x 60, 1x 75, 1x 178, 1x 187, 2x 188							
<b>Sample B</b>		3,75	0,18	4,7	14		CVP	3,78	0,035	20%	3,02	4,54	14	13	93
(58) Beckman Coulter (AU)		3,67	0,096	2,6	5	0							5		
Other					9	0							9		
								1x 1, 3x 60, 1x 75, 1x 178, 1x 187, 2x 188							